Competition record
Novo Nordisk
Deep profile · 0 linked library matters
Novo Nordisk makes Ozempic and Wegovy, the semaglutide drugs used for diabetes and weight loss. Eli Lilly is the rival that matters, and patients still depend on pen-filling lines and on which pharmacy benefit manager covers the prescription.
Overview
The company is based in Denmark and sells Ozempic for type 2 diabetes and Wegovy for obesity, both using semaglutide. Eli Lilly contests the same prescribers with Mounjaro and Zepbound, which use tirzepatide.
Pens have been the bottleneck, so Novo Nordisk has expanded fill-finish capacity in Denmark and North Carolina and added three plants that previously belonged to Catalent. A written prescription does not help a pharmacy that has no pens on the shelf.
CVS Caremark, Express Scripts, and OptumRx decide whether an employer plan pays for Wegovy or only for diabetes uses of semaglutide. Those formulary choices set the demand the factories then have to meet.
Competition footprint
Patent life on semaglutide and on the injection device decides how long rivals and later generics wait.
Fill-finish capacity is a physical constraint for every country Novo Nordisk supplies.
Formulary placement at the three large pharmacy benefit managers moves volume faster than a change in list price.
Consumer & business angle
Patients see coverage denials and pharmacy stockouts even after a doctor has chosen a brand.
Employers bargaining over obesity coverage know a yes decision sends volume to Novo Nordisk or to Lilly.
What to watch
- Semaglutide and device patents, including any expiry that would let another pen reach pharmacies.
- Fill-finish expansions and the annual formulary decisions at CVS Caremark, Express Scripts, and OptumRx.
Markets
GLP-1 medicines · diabetes drugs · obesity drugs
Also known as: ozempic, wegovy, semaglutide
Conduct themes
Linked cases in the library
No linked matters in the current library yet. The narrative above is still a market-power primer — check primary sources for live disputes.